[Source: Ken Alltucker, The Arizona Republic ] - Sunshine and skin damage have prompted a San Diego biotechnology company to expand in Arizona to develop a line of anti-aging skin products.
Histogen Inc. has opened a Tempe office and plans to begin selling three new skin-care products in the first quarter of 2009.
The company said it uses a stem-cell-like technology to foster a skin product derived from skin discarded from infants after circumcisions.
The company wants to parlay revenue collected from the sale of aesthetic products to fund research in areas such as cardiovascular and wound healing.
It's the same playbook sketched out by other Arizona biotechnology companies such as Tucson-based Niadyne Development: develop anti-aging skin products backed by science to raise cash while focusing on a bigger prize of health research.
The Tempe division is called Histogen Aesthetics.
President Lawrence Rheins said the company chose Arizona to launch its aesthetics business due to the Phoenix-area's large network of dermatologists and plastic surgeons focused on cosmetic and anti-aging procedures as well as the state's growing biotechnology hub.
"Everybody who lives here gets photo (sun) damage," said Rheins, who previously served as a director at Hill Top Research in Scottsdale and an assistant dermatology professor at the University of Cincinnati. "There is a real need for these types of products because of the desert climate and the intense sun."
Histogen CEO Gail Naughton was the co-founder of Advanced Tissue Sciences, a former San Diego biotech company that had a promising skin-patch technology to treat burns and wounds.
The company eventually filed bankruptcy amid heavy debt and a struggle to get Food and Drug Administration approval for a key product.
Naughton, now a dean of the college of business administration at San Diego State University, has reloaded with Rheins and several of her former Advanced Tissue colleagues.
Of Histogen's first 25 employees, 18 worked together at Advanced Tissue, Rheins said.
"It is clearly the reason we were able to start as fast as we were able to," he said.
Histogen's Tempe office has four employees, with plans to expand to about 20 workers as the company launches its line of skin products targeting baby boomers and others. The positions will mainly be sales and marketing.
Rheins said the company expects its non-prescription products will be sold by plastic surgeons and dermatologists and distributed by a Tempe company, Secure Medical. Secure Medical CEO John Rao also sits on the board of Histogen, and Secure Medical is an investor.
Histogen's products will be made from an ingredient the company calls ReGenica, which can be used for skin, hair and nail care.
The company said its technology mimics the embryo, allowing the growth of protein-rich material that is similar to what is found in young skin.
Rheins said the company's initial products will include a gel that can be applied to skin after laser resurfacing. It also will unveil anti-aging lotions that are applied day and night.
Earlier this year, Histogen unveiled a kit to grow stem cells, called BioNuesis.
The Tempe division expects to expand with other skin offerings such as dermal fillers or treatments for skin conditions such as acne or rosacea.
Rheins said Histogen has no plans to conduct research at its Tempe office, but the company may conduct clinical trials here.
The parent company, which formed last year, believes the technology can be used to eventually have many beneficial therapeutic uses, including regenerating cells that can help treat cardiovascular patients and heal wounds.
Showing posts with label Melanoma. Show all posts
Showing posts with label Melanoma. Show all posts
Monday, October 27, 2008
Monday, May 19, 2008
Researchers close in on new melanoma gene
[Source: TGen] - Genome-wide study rapidly scans DNA for clues, narrows search
It has long been known that prolonged exposure to the suns harmful UV rays can lead to Melanoma, the deadliest form of skin cancer. An unanswered question, however, is why some people are more likely to develop melanoma than others. Despite years of research and clinical development, melanoma incidences continue to rise around the world. According to the National Cancer Institute, the percentage of people in the United States who develop melanoma each year has more than doubled in the past 30 years.
Results published today from a study led by researchers from The Translational Genomic Research Institute (TGen) in Phoenix, Arizona and The Queensland Institute of Medical Research (QIMR), Queensland, Australia, however, may yet change these statistics. The team is close to discovering a new gene that could help explain variation in melanoma risk.
In a report appearing in an Advance Online Publication (AOP) of the journal Nature Genetics, the researchers and their colleagues identify a region on chromosome 20 (20q11.22) that influences a person’s risk of developing melanoma.
According to Dr Kevin Brown, TGen Investigator and the paper's co-first author, compared to other genetic research focusing on familial (or inherited) cases of melanoma, this finding holds implications for the general population
"We're closing in on genetic variants which cause 16 percent of the population to be at nearly double the increased risk of developing the disease. In public health terms, this finding is highly significant," Dr. Brown said.
The researchers narrowed the gene location through a genome-wide association study - a first in melanoma research. Genome-wide studies involve rapidly scanning DNA of many people to find genetic variations associated with a particular disease. After identifying new genetic associations, researchers can use the information to develop better strategies to detect, treat and prevent the disease.
"The aim of our work is to identify and understand the genetic factors influencing melanoma so we can better predict risk estimates," said QIMR's Dr. Stuart MacGregor, co-first author on the study. "This in turn, means people will be better informed and can take the right precautions to avoid developing this increasingly common cancer."
How The Study Works
A genome-wide association study involves scanning the DNA from two sets of individuals: those with a particular disease (cases) and those of similar individuals without the disease (controls). The DNA of each sample then undergoes examination for strategically selected markers of genetic variation, called single nucleotide polymorphisms, or SNPs. If certain genetic variations are found to be significantly more frequent in people with the disease compared to people without disease, those variations are said to be "associated" with the disease. The associated genetic variations can serve as roadmaps to the region of the human genome where the disease-causing gene resides.
The study - whose data collection began 20 years ago - involved more than 4,000 Australian samples (2,019 cases and 2,105 controls) and was a joint project between Australian, American and European research groups.
About Melanoma
According to the National Cancer Institute's on-line booklet, What You Need to Know About Melanoma, melanoma is a form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.
Melanoma is the most serious type of cancer of the skin. Each year in the United States, more than 64,800 people learn they have melanoma and approximately 8,400 will die from the disease. The disease is particularly prevalent in the Southwest, particularly Arizona, where the incidence rate is double the national average and is becoming more common every year.
Funding
Funding for Dr. Browns lab was provided by Melanoma Research Foundation (MRF) Research Grant Program, whose purpose is to support promising medical research that will further the goal of developing an effective treatment and possible cure of malignant melanoma, while encouraging scientists and clinicians to join in this mission. The Foundation funds both junior and senior researchers. In both grant programs, emphasis will be placed on projects that explore innovative approaches to understanding melanoma and its treatment. Both basic and clinical research projects will be considered.
"Each year, we receive grant requests from some of the best and brightest melanoma researchers in the world," said Linda Pilkington, Executive Director, Melanoma Research Foundation. "The research conducted by scientists like Dr. Brown gives melanoma patients the hope they need and deserve - hopefully one day leading to a cure for this deadly disease."
About the Melanoma Research Foundation
The Melanoma Research Foundation (MRF) is the largest private, national organization devoted to melanoma in the United States. The Foundation is committed to the support of medical research in finding effective treatments and eventually a cure for melanoma. The Foundation also educates patients and physicians about prevention, diagnosis and treatment of melanoma, while acting as an advocate for the melanoma community to raise awareness of this disease and the need for a cure. The MRF Web site is the premiere source for melanoma information seekers. More information is available at www.melanoma.org.
Media Contacts:
TGen
Galen Perry
Phone: (602) 343-8423
E-mail: gperry@tgen.org
QIMR
Felipe Beltran, QIMR Media Relations Officer
Phone: (07) 3362 0291
E-mail: Felipe.Beltran@qimr.edu.au
MRF
Heather R. Huhman
Phone: (202) 742-5259
E-mail: Heather@JonesPA.com
It has long been known that prolonged exposure to the suns harmful UV rays can lead to Melanoma, the deadliest form of skin cancer. An unanswered question, however, is why some people are more likely to develop melanoma than others. Despite years of research and clinical development, melanoma incidences continue to rise around the world. According to the National Cancer Institute, the percentage of people in the United States who develop melanoma each year has more than doubled in the past 30 years.
Results published today from a study led by researchers from The Translational Genomic Research Institute (TGen) in Phoenix, Arizona and The Queensland Institute of Medical Research (QIMR), Queensland, Australia, however, may yet change these statistics. The team is close to discovering a new gene that could help explain variation in melanoma risk.
In a report appearing in an Advance Online Publication (AOP) of the journal Nature Genetics, the researchers and their colleagues identify a region on chromosome 20 (20q11.22) that influences a person’s risk of developing melanoma.
According to Dr Kevin Brown, TGen Investigator and the paper's co-first author, compared to other genetic research focusing on familial (or inherited) cases of melanoma, this finding holds implications for the general population
"We're closing in on genetic variants which cause 16 percent of the population to be at nearly double the increased risk of developing the disease. In public health terms, this finding is highly significant," Dr. Brown said.
The researchers narrowed the gene location through a genome-wide association study - a first in melanoma research. Genome-wide studies involve rapidly scanning DNA of many people to find genetic variations associated with a particular disease. After identifying new genetic associations, researchers can use the information to develop better strategies to detect, treat and prevent the disease.
"The aim of our work is to identify and understand the genetic factors influencing melanoma so we can better predict risk estimates," said QIMR's Dr. Stuart MacGregor, co-first author on the study. "This in turn, means people will be better informed and can take the right precautions to avoid developing this increasingly common cancer."
How The Study Works
A genome-wide association study involves scanning the DNA from two sets of individuals: those with a particular disease (cases) and those of similar individuals without the disease (controls). The DNA of each sample then undergoes examination for strategically selected markers of genetic variation, called single nucleotide polymorphisms, or SNPs. If certain genetic variations are found to be significantly more frequent in people with the disease compared to people without disease, those variations are said to be "associated" with the disease. The associated genetic variations can serve as roadmaps to the region of the human genome where the disease-causing gene resides.
The study - whose data collection began 20 years ago - involved more than 4,000 Australian samples (2,019 cases and 2,105 controls) and was a joint project between Australian, American and European research groups.
About Melanoma
According to the National Cancer Institute's on-line booklet, What You Need to Know About Melanoma, melanoma is a form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.
Melanoma is the most serious type of cancer of the skin. Each year in the United States, more than 64,800 people learn they have melanoma and approximately 8,400 will die from the disease. The disease is particularly prevalent in the Southwest, particularly Arizona, where the incidence rate is double the national average and is becoming more common every year.
Funding
Funding for Dr. Browns lab was provided by Melanoma Research Foundation (MRF) Research Grant Program, whose purpose is to support promising medical research that will further the goal of developing an effective treatment and possible cure of malignant melanoma, while encouraging scientists and clinicians to join in this mission. The Foundation funds both junior and senior researchers. In both grant programs, emphasis will be placed on projects that explore innovative approaches to understanding melanoma and its treatment. Both basic and clinical research projects will be considered.
"Each year, we receive grant requests from some of the best and brightest melanoma researchers in the world," said Linda Pilkington, Executive Director, Melanoma Research Foundation. "The research conducted by scientists like Dr. Brown gives melanoma patients the hope they need and deserve - hopefully one day leading to a cure for this deadly disease."
About the Melanoma Research Foundation
The Melanoma Research Foundation (MRF) is the largest private, national organization devoted to melanoma in the United States. The Foundation is committed to the support of medical research in finding effective treatments and eventually a cure for melanoma. The Foundation also educates patients and physicians about prevention, diagnosis and treatment of melanoma, while acting as an advocate for the melanoma community to raise awareness of this disease and the need for a cure. The MRF Web site is the premiere source for melanoma information seekers. More information is available at www.melanoma.org.
Media Contacts:
TGen
Galen Perry
Phone: (602) 343-8423
E-mail: gperry@tgen.org
QIMR
Felipe Beltran, QIMR Media Relations Officer
Phone: (07) 3362 0291
E-mail: Felipe.Beltran@qimr.edu.au
MRF
Heather R. Huhman
Phone: (202) 742-5259
E-mail: Heather@JonesPA.com
Subscribe to:
Posts (Atom)